Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5944_Библиотеки_им_академика_М_И_Перельмана
.pdf
Applications of Natural Products in Drug Delivery
https://t.me/medicina_free
219
To form therapeutics through multiple purposes, delivery systems can
also give the potential. Radwan et al. explained numerous applications of
ganoderic acids that are extracted by employing methanol from the fungus
Ganoderma lucidum, along with nanoparticles intended for cancer therapy.
In old medicine, this specic mushroom has been employed for decades.
Inside hydrophobic pockets through encapsulating a lipophilic adjacent
infrared dye in the polymeric matrix of polyacrylic acid-coated IONPs (iron
oxide nanoparticles) in common with the anticancer drug, the nanoparticles
can be employed for imaging along with therapy (Garg and Gupta, 2010).
The advance of nanoparticles that are infused with ganoderic acid has
also empowered to improve targeting and decrease toxic side effects by a
combination of the cancer cell-targeting moieties and anticancer drug. There
is a perception that drug doses employed to cure tumor cells can also disturb
normal cells, but usage of a drug-delivery system permits the gathering
of the drug just in cancer cells. For that matter, in cancer cells, folic acid
along with GA (gum arabic) was encapsulated to aim the folate receptor
that is overexpressed, therefore allowing greater drug doses of GA to gather
in the tumors and decrease off-target side effects (Bagli et al., 2016). A
micelle-based delivery system has also been employed for improving the
biodistribution and bioavailability of further mushroom compounds like
Flammulina velutipes sterols. Delivery systems in these cases have several
goals such as their use to provide sustained delivery, enhance stability,
decrease toxicity, advance targeting, and give shield from chemical or
physical deprivation of compound natural compounds (Prasad et al., 2014).
To give constant quality of therapeutic molecules is the main challenge of
working with mushrooms. These contain trouble in rening mushrooms,
the necessity of great engineering practice of cultivation approaches, and
forming complete methods of purication, isolation, identication, and
challenging of bioactive compounds to clarify the mechanisms of action
(Rahimi et al., 2016). The major challenge with this research is the absence of
calibration and this has incomplete the scientic trials carried out. Effective
natural antibiotics are one area that may be relevant such as, which have
restricted use because of insolubility problems and have essential novel
blend procedures to expand their bioavailability or use of delivery systems
to advance targeting and decrease the introduction of antibiotic resistance
(Li et al., 2013; Sherry et al., 2013).
220
https://t.me/medicina_free
Natural Compounds: An Introduction
7.4. IMPACT OF DRUG-DELIVERY SYSTEMS IN
BIOTHERAPEUTICS DEVELOPMENTS
The overview of targeting moieties on the surfaces of delivery systems can
be used to aim the therapeutic agents to specific tissues, which will improve
the discrimination of these plant extract formulations. At the desired site, this
can improve the accretion of the encapsulated product, which will improve
its efficacy (Sinico et al., 2005). This presents the additional face of the drug
discovery coin that depends on the advance of new biotherapeutics. The
change in distinction toward the advance of protein therapeutics or nucleic
acid-based drugs is in portion reflected through the increasing occurrence of
biologic agents in the collection of main biopharmaceutical companies. The
yearly amount of first sanctions was in the range of 5–8 in 2014 forward,
in Phase III studies in 2016 through 53 novel antibody therapeutics, and
around 210 new antibody therapeutics in separately of Phase I and II of
scientific development (Rajendran et al., 2013).
In the application of drug-delivery systems, numerous developments
have been attained for biotherapeutics delivery. This can be required
to improve the start of therapeutic action and allows administration of
biomolecules through noninvasive routes like inhalation or oral to evade
intravenous administration. For instance, biotherapeutics like glucagon,
growth hormone, or can be efciently delivered through inhalation therapy
by the usage of a suitable delivery system (Figure 7.4) (Verma et al., 2013;
Yuan et al., 2016).
Figure 7.4: Comparison of conventional and nanocarriers based novel drug
delivery systems.
Source: https://www.eurekaselect.com/172285/article.
Applications of Natural Products in Drug Delivery
https://t.me/medicina_free
221
To advance the pharmacokinetics of very degradable compounds,
the drug-delivery systems can be employed like proteins and peptides
via shielding these agents and improving their half-lives. The delivery of
insulin through inhalation or noninvasive oral routes is one of the important
developments. The insulin oral delivery is taken as to be the ideal route of
delivery as it will move straight to the liver, which for insulin action is the
key site (Yuan et al., 2016). Furthermore, it will take over the needle-anxiety
barricade that is related to delivering insulin hypodermically. Nevertheless,
it is extremely exciting to deliver insulin by employing this method for
various reasons, such as harsh chemicals pH inactivation, in the gastral
tract, cellular, and enzymatic barriers. All these can guide to extremely
poor insulin bioavailability (<1%). New researches have been conducted
by employing liposomes, microemulsions, and microspheres to improve
the bioavailability of insulin when it is managed orally. In these vehicles,
the encapsulation of proteins like insulin will defend them from the severe
stomach environment (Cao et al., 2007; Zhaowu et al., 2009). In the case of
2
inhaled insulin, because of the large surface area (100 m
) lungs have been
beset for insulin delivery and the beginning of action subsequent inhalation.
Inhaled insulin sprays into two formulations, liquid, or dry powder. Dry
powder preparations are measured to be more constant and for delivery need
fewer complex devices. Pzer formed a product named Exubera that was the
rst ofcial inhaled insulin therapy to be on the market. In 2006 it gained
approval through the US FDA. Nevertheless, in October 2007 because of
poor patient acceptance and very low sales, the product was withdrawn.
For Exubera’s failure, various reasons were accountable, as the bulk and
size of the inhaler device, needed daily cleaning, per dose patients had
to execute over one inhalation to attain the therapeutic effect. However,
when an appropriate medical device is intended, the potential is there to
overwhelmed these challenges (Bhattacharya, 2009; Li et al., 2009).
ADCs (Antibody-drug conjugates) are an additional example of the
usage of drug-delivery systems through biotherapeutics. ADCs are taken
as an example of Paul Ehrlich’s ‘magic bullet’ theory for custom-made
and targeted drug delivery to ght to invade malignant or microbe’s cells.
ADCs have conrmed their worth in lethal diseases such as cancer, where
the normal chemotherapies are disreputably related to restricted selectivity
contrary to cancer cells guiding to a small therapeutic space that can next
limit their efcacy. The ADCs concept depends on the combination of
the high stability and specicity prole of antibodies with the antitumor
strength of very cytotoxic small-molecule drugs ‘warheads’ to generate a
222
https://t.me/medicina_free
Natural Compounds: An Introduction
discriminating treatment with improved therapeutic space and decreased
off-target toxicity. Albeit the concentrated attention of ADCs progress has
been just on cancer, their misuse has been prolonged to other applications via
the improvement of immunosuppressants, and antibody-antibiotic couples.
The rst-generation ADCs, signied by Wyeth’s Mylotarg
R
, discovered
unsatisfactory, inadequate toxicity, and potency effects that guide to removal
of this conjugate solution from the market in 2010. The advancement of
more effective (100–1000 fold) cytotoxic agents, such as maytansinoid
nd
and auristatin, have a guide to the approval of two 2
Kadcyla
through both the EMA and FDA. The 2
R
(trastuzumab-emtansine) and AcetrisR (brentuximab-vedotin),
nd
generation ADCs even with these
generation ADCs,
approvals are still related with disadvantages like heterogeneity resultant
from stochastic connection strategies, the development of resistance, and
rd
restricted penetration of solid tumors. Therefore, 3
generation ADCs have
appeared with important attention on site-specic conjugation to conrm
homogenous ADCs with well-dened antibody-drug ratio. The great
potential of these conjugate solutions has developed the biopharma R&D,
with presently above 50 ADCs experiencing clinical evaluation. As per new
market analysis, the ADC worldwide market is expected to show a vigorous
growth signied through multiple annual growth rates of 22% during 2017–
2022, mainly determined through a large number of ADC applicants in the
pipeline, increasing amount cancer patients and a broader therapeutic gap
presented through these ADCs.
Despite the widespread variances between the current conjugation
methods, which were broadly revised somewhere else, their alterations
have mostly intensive on warhead optimization, target selection, design of
appropriate linkers, selection of precise antibodies, and alternative and site-
specic conjugation approaches to improve potency. ADCs are unceasingly
revealing great probable in both non-oncological and oncological indications.
In preclinical or clinical stages several drug candidates have failed because
of toxicity or lack of selectivity issues. For this precise reason, the ADC
approach offers a valued chance for these molecules to be re-evaluated,
especially with the substantial development of conjugation technologies and
antibody engineering.
Applications of Natural Products in Drug Delivery
https://t.me/medicina_free
223
One more example for the application of drug-delivery systems through
biotherapeutics comprises the delivery of numerous kinds of nucleic acids
like nucleotides, plasmids. By enabling their accumulation and approval by
the target site, the drug-delivery systems expand the application of these
nucleic acid therapeutics. The delivery of short-interfering RNA (siRNA)
is one of the exciting examples. siRNA combined of short double-stranded
nucleic acids that can silence specic protein expression via a mechanism
called RNA interference. This is a eld full of research required with very
promising results.
224
https://t.me/medicina_free
Natural Compounds: An Introduction
REFERENCES
1. Al Qaraghuli, M. M., & Ferro, V. A., (2017). Analysis of the binding
conguration and surface adaptation of different crystallized single-
domain antibodies in response to various antigens. J. Mol. Recog.,
30(4), 1–10.
2. Ali, S., Igoli, J., & Clements, C., (2013). Antidiabetic and antimicrobial
activities of fractions and compounds isolated from Berberis brevissima
Jafri and Berberis parkeriana Schneid. Bangladesh J. Pharmacol.,
8(3), 336–342.
3. Allen, T. M., & Cullis, P. R., (2013). Liposomal drug delivery systems:
From concept to clinical applications. Adv. Drug Deliv. Rev., 65(1),
36–48.
4. Alonezi, S., Tusiimire, J., & Wallace, J., (2016). Metabolomic proling
of the effects of melittin on cisplatin-resistant and cisplatin sensitive
ovarian cancer cells using mass spectrometry and biology microarray
technology. Metabolites, 6(4), 35.
5. Alzahrani, A., Abbott, G., Young, L., Igoli, J., Gray, A., & Ferro, V.,
(2016). Phytochemical and biological investigation of Calliandra
surinamensis as a potential treatment for diabetes. Planta Medica,
81(S 01), P385.
6. Aqil, F., Munagala, R., Jeyabalan, J., & Vadhanam, M. V., (2013).
Bioavailability of phytochemicals and its enhancement by drugdelivery systems. Cancer Lett., 334(1), 133–141.
7. Atanasov, A. G., Waltenberger, B., & Pferschy-Wenzig, E. M., (2015).
Discovery and resupply of pharmacologically active plant-derived
natural products: A review. Biotechnol. Adv., 33(8), 1582–1614.
8. Bagli, E., Goussia, A., Moschos, M. M., Agnantis, N., & Kitsos, G.,
(2016). Natural compounds and neuroprotection: Mechanisms of
action and novel delivery systems. In Vivo, 30(5), 535–547.
9. Balunas, M. J., & Kinghorn, A. D., (2005). Drug discovery from
medicinal plants. Life Sci., 78(5), 431–441.
10. Bhattacharya, S., (2009). Phytosomes: Emerging strategy in delivery
of herbal drugs and nutraceuticals. Pharma Times, 41(3), 9–12.
11. Bilia, A., (2012). Improving on nature: The role of nanomedicine in the
development of clinical natural drugs. Planta Medica, 78(11), IL48.
Applications of Natural Products in Drug Delivery
https://t.me/medicina_free
225
12. Bucar, F., Wube, A., & Schmid, M., (2013). Natural product isolation
- how to get from biological material to pure compounds. Nat. Prod.
Rep., 30(4), 525–545.
13. Cao, F. H., Ouyang, W. Q., & Wang, Y. P., (2007). Study of preparation
of matrin nanoemulsion and its anti-oxidation on mice. J. Northwest
Sci. Tech. Univer. Agric. Forest., 3, 61–64.
14. Chen, Y., Lin, X., Park, H., & Greever, R., (2009). Study of artemisinin
nanocapsules as anticancer drug-delivery systems. Nanomedicine,
5(3), 316–322.
15. Chuan, L., Zhang, J., & Yu-Jiao, Z., (2015). Biocompatible and
biodegradable nanoparticles for enhancement of anticancer activities
of phytochemicals. Chin. J. Nat. Med., 13(9), 641–652.
16. Cragg, G. M., & Newman, D. J., (2001). Natural product drug discovery
in the next millennium. Pharm. Biol., 39(1), 8–17.
17. Cragg, G. M., Grothaus, P. G., & Newman, D. J., (2009). Impact of
natural products on developing new anticancer agents. Chem. Rev.,
109(7), 3012–3043.
18. Desai, N., (2012). Challenges in the development of nanoparticle-
based therapeutics. AAPS J., 14(2), 282–295.
19. Ganesan, P., Arulselvan, P., & Choi, D. K., (2017). Phytobioactive
compound-based nanodelivery systems for the treatment of Type 2
diabetes mellitus-current status. Int. J. Nanomed., 12, 1097.
20. Garg, R., & Gupta, G., (2010). Gastroretentive oating microspheres
of silymarin: Preparation and in vitro evaluation. Trop. J. Pharm. Res.,
9(1), 58–66.
21. Gebril, A. M., Lamprou, D. A., Alsaadi, M. M., Stimson, W. H.,
Mullen, A. B., & Ferro, V. A., (2014). Assessment of the antigen-
specic antibody response induced by mucosal administration of a
GnRH conjugate entrapped in lipid nanoparticles. Nanomedicine,
10(5), 971–979.
22. Hans, M., & Lowman, A., (2002). Biodegradable nanoparticles for
drug delivery and targeting. Curr. Opin. Solid State Mater. Sci., 6(4),
319–327.
23. Hou, J., & Zhou, S., (2008). Formulation and preparation of glycyrrhizic
acid solid lipid nanoparticles. ACTA Academiae Medicinae Militaris
Tertiae, 30(11), 1043–1045.
226
https://t.me/medicina_free
Natural Compounds: An Introduction
24. http://csdd.tufts.edu/news/complete story/pr tuftscsdd 2014coststudy
(accessed on 11 June 2021).
25. Li, D. C., Zhong, X. K., & Zeng, Z. P., (2009). Application of targeted
drug delivery system in Chinese medicine. J. Control. Rel., 138(2),
103–112.
26. Li, H., Li, S., & Duan, H., (2007). Preparation of liposomes containing
extracts of Tripterygium wilfordii and evaluation of its stability.
Zhongguo Zhong Yao Za Zhi, 32(20), 2128–2131.
27. Mack, A., Relman, D. A., & Choffnes, E. R., (2011). Antibiotic
Resistance: Implications for Global Health and Novel Intervention
Strategies: Workshop Summary (Vol. 1, pp. 1–10). National Academies
Press, Washington, D.C., USA.
28. Miele, E., Spinelli, G. P., & Miele, E., (2012). Nanoparticle-based
delivery of small interfering RNA: Challenges for cancer therapy. Int.
J. Nanomed., 7, 3637–3657.
29. Nam, J. S., Sharma, A. R., Nguyen, L. T., Chakraborty, C., Sharma, G.,
& Lee, S. S., (2016). Application of bioactive quercetin in monotherapy:
From nutrition to nanomedicine. Molecules, 21(1), 108.
30. Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of
new drugs from 1981 to 2014. J. Nat. Prod., 79(3), 629–661.
31. Newman, D. J., & Cragg, G. M., (2007). Natural products as sources of
new drugs over the last 25 years. J. Nat. Prod., 70(3), 461–477.
32. Niwasabutra, K., Igoli, J., Young, L., Gray, A., & Ferro, V., (2016).
Effects of crude extracts from mushrooms on different cancer cell
lines. Planta Medica, 81(S 01), P320.
33. Obeid, M. A., Gebril, A. M., Tate, R. J., Mullen, A. B., & Ferro, V. A.,
(2017). Comparison of the physical characteristics of monodisperse
non-ionic surfactant vesicles (NISV) prepared using different
manufacturing methods. Int. J. Pharm., 521(1), 54–60.
34. Obeid, M. A., Khadra, I., Mullen, A. B., Tate, R. J., & Ferro, V. A.,
(2017). The effects of hydration media on the characteristics of non-
ionic surfactant vesicles (NISV) prepared by microuidics. Int. J.
Pharm., 516(1), 52–60.
35. Pandey, S., Goyani, M., Devmurari, V., & Fakir, J., (2009).
Transferosomes: A novel approach for transdermal drug delivery. Der
Pharmacia Lettre, 1(2), 143–150.
Applications of Natural Products in Drug Delivery
https://t.me/medicina_free
227
36. Parveen, S., Misra, R., & Sahoo, S. K., (2012). Nanoparticles: A boon to
drug delivery, therapeutics, diagnostics, and imaging. Nanomedicine,
8(2), 147–166.
37. Pelaz, B., Alexiou, C., & Alvarez-Puebla, R. A., (2017). Diverse
applications of nanomedicine. CS Nano, 11, 2313−2381.
38. Peters, S., (2014). Cost to Develop and Win Marketing Approval for a
New Drug is $2.6 Billion (Vol. 1, pp. 1–7).
39. Prasad, S., Tyagi, A. K., & Aggarwal, B. B., (2014). Recent
developments in delivery, bioavailability, absorption, and metabolism
of curcumin: The golden pigment from golden spice. Cancer Res.
Treat., 46(1), 2–18.
40. Rahimi, H. R., Nedaeinia, R., Shamloo, A. S., Nikdoust, S., & Oskuee,
R. K., (2016). Novel delivery system for natural products: Nanocurcumin formulations. Avicenna J. Phytomed., 6(4), 383.
41. Rajendran, R., Radhai, R., Kotresh, T., & Csiszar, E., (2013).
Development of antimicrobial cotton fabrics using herb loaded
nanoparticles. Carbohydr. Polym., 91(2), 613–617.
42. Sasidharan, S., Chen, Y., Saravanan, D., Sundram, K., & Latha, L.
Y., (2011). Extraction, isolation, and characterization of bioactive
compounds from plants’ extracts. Afr. J. Tradit. Complement. Altern.
Med., 8(1), 1–10.
43. Shen, B., (2015). A new golden age of natural products drug discovery.
Cell, 163(6), 1297–1300.
44. Sherry, M., Charcosset, C., Fessi, H., & Greige-Gerges, H., (2013).
Essential oils encapsulated in liposomes: A review. J. Liposome Res.,
23(4), 268–275.
45. Sikarwar, M. S., Sharma, S., Jain, A. K., & Parial, S., (2008). Preparation,
characterization, and evaluation of marsupsin-phospholipid complex.
AAPS PharmSciTech., 9(1), 129–137.
46. Sinico, C., Logu, A. D., & Lai, F., (2005). Liposomal incorporation of
Artemisia arborescens L. essential oil and in vitro antiviral activity.
Eur. J. Pharm. Biopharm., 59(1), 161–168.
47. Verma, H., Prasad, S. B., & Yashwant, S. H., (2013). Herbal drug
delivery system: A modern era prospective. Int. J. Current Pharm. Rev.
Res., 4, 88–101.
228
https://t.me/medicina_free
Natural Compounds: An Introduction
48. Watkins, R., Wu, L., Zhang, C., Davis, R. M., & Xu, B., (2015).
Natural product-based nanomedicine: Recent advances and issues. Int.
J. Nanomed., 10, 6055.
49. Yuan, H., Ma, Q., Ye, L., & Piao, G., (2016). The traditional medicine
and modern medicine from natural products. Molecules, 21(5), PII:
E559.
50. Zamboni, W. C., Torchilin, V., & Patri, A. K., (2012). Best practices
in cancer nanotechnology: Perspective from NCI nanotechnology
alliance. Clin. Cancer Res., 18(12), 3229–3241.
51. Zhaowu, Z., Xiaoli, W., Yangde, Z., & Nianfeng, L., (2009). Preparation
of matrine ethosome, its percutaneous permeation in vitro and antiinammatory activity in vivo in rats. J. Liposome Res., 19(2), 155–162.
Соседние файлы в папке Библиотека им академика М.И. Перельмана